Eman G. Youssef

Bani Suwayf, BNS 62511, Egypt

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Diabetes and Immunosuppression Drive Distinct Patterns of Candidozyma auris Skin Colonization and Dissemination in Mice.

Diabetes and Immunosuppression Drive Distinct Patterns of Candidozyma auris Skin Colonization and Dissemination in Mice.

Journal: bioRxiv : the preprint server for biology
Published: June 05, 2026

β-Glucan Chitosan Particle Provides Cross-Protection Against Multi-Drug- Resistant Candida auris.

β-Glucan Chitosan Particle Provides Cross-Protection Against Multi-Drug- Resistant Candida auris.

Journal: Research square
Published: December 08, 2025

Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates.

Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates.

Journal: Antimicrobial agents and chemotherapy
Published: December 05, 2025

β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.

β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.

Journal: NPJ vaccines
Published: October 24, 2025

Next-generation Candida albicans recombinant Als3p and Hyr1p dual antigen vaccine for invasive Candida infections.

Next-generation Candida albicans recombinant Als3p and Hyr1p dual antigen vaccine for invasive Candida infections.

Journal: Research square
Published: September 15, 2025

Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections.

Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections.

Journal: Scientific reports
Published: August 01, 2025

In Silico Design of a Multiepitope Vaccine Against Intestinal Pathogenic Escherichia coli Based on the 2011 German O104:H4 Outbreak Strain Using Reverse Vaccinology and an Immunoinformatic Approach.

In Silico Design of a Multiepitope Vaccine Against Intestinal Pathogenic Escherichia coli Based on the 2011 German O104:H4 Outbreak Strain Using Reverse Vaccinology and an Immunoinformatic Approach.

Journal: Diseases (Basel, Switzerland)
Published: July 17, 2025

A spatial transcriptomic atlas of the host response to oropharyngeal candidiasis.

A spatial transcriptomic atlas of the host response to oropharyngeal candidiasis.

Journal: mBio
Published: June 30, 2025

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis.

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis.

Journal: Antimicrobial agents and chemotherapy
Published: April 01, 2025

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response.

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response.

Journal: Science translational medicine
Published: March 12, 2025

Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis.

Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis.

Journal: Antimicrobial agents and chemotherapy
Published: April 30, 2024

Efficacy of an oral lipid nanocrystal (LNC) formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis.

Efficacy of an oral lipid nanocrystal (LNC) formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis.

Journal: bioRxiv : the preprint server for biology
Published: December 04, 2023
Showing 1-12 of 20

Last Updated: 09/26/2026